These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 25426701

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
    Hussein Z, Lim-Abrahan MA, Jain AB, Goh SY, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
    [Abstract] [Full Text] [Related]

  • 25. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
    Hermansen K, Colombo M, Storgaard H, ØStergaard A, Kølendorf K, Madsbad S.
    Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
    [Abstract] [Full Text] [Related]

  • 26. Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.
    Liebl A, Prusty V, Valensi P, Kawamori R, Christiansen JS, Palmer AJ, Balschmidt P, Ligthelm R, Mohan V.
    Drugs; 2012 Jul 30; 72(11):1495-520. PubMed ID: 22818015
    [Abstract] [Full Text] [Related]

  • 27. Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.
    Latif ZA, Pathan MF, Siddiqui MN, Sobhan MJ, Rahman MM, Ashrafuzzaman SM.
    Diabetes Res Clin Pract; 2013 Apr 30; 100 Suppl 1():S30-4. PubMed ID: 23647716
    [Abstract] [Full Text] [Related]

  • 28. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ, Gylvin T, DeLuzio T, Raskin P.
    Endocr Pract; 2011 Apr 30; 17(1):41-50. PubMed ID: 20713345
    [Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M, Azoulay M, Greiner RA.
    Int J Clin Pharmacol Ther; 2011 Mar 30; 49(3):217-30. PubMed ID: 21329624
    [Abstract] [Full Text] [Related]

  • 30. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
    Ridderstråle M, Jensen MM, Gjesing RP, Niskanen L.
    J Med Econ; 2013 Mar 30; 16(4):468-78. PubMed ID: 23384160
    [Abstract] [Full Text] [Related]

  • 31. [Comparison on the efficacy of biphasic insulin aspart 30 and premixed human insulin 30/70 through continuous glucose monitoring system].
    Chen SF, Li H.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Aug 30; 32(8):827-9. PubMed ID: 22093477
    [Abstract] [Full Text] [Related]

  • 32. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
    Rys P, Wojciechowski P, Siejka S, Małecki P, Hak L, Malecki MT.
    Int J Clin Pract; 2014 Mar 30; 68(3):304-13. PubMed ID: 24471814
    [Abstract] [Full Text] [Related]

  • 33. Switch from biphasic human insulin 30 to biphasic insulin aspart 30 in Pakistani subjects.
    Hassan MI, Aamir AH, Miyan Z, Siddiqui LA, Mahmood S, Vohra EA.
    J Pak Med Assoc; 2013 Oct 30; 63(10):1290-4. PubMed ID: 24392563
    [Abstract] [Full Text] [Related]

  • 34. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
    Dieuzeide G, Chuang LM, Almaghamsi A, Zilov A, Chen JW, Lavalle-González FJ.
    Prim Care Diabetes; 2014 Jul 30; 8(2):111-7. PubMed ID: 23953707
    [Abstract] [Full Text] [Related]

  • 35. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Linjawi S, Sothiratnam R, Sari R, Andersen H, Hiort LC, Rao P.
    Prim Care Diabetes; 2015 Oct 30; 9(5):370-6. PubMed ID: 25488587
    [Abstract] [Full Text] [Related]

  • 36. Clinical experience with BIAsp 30: Results from the Bangladesh cohort of the global A1chieve study.
    Latif ZA, Pathan MF, Mannan MA, Siddiqui MN, Ashrafuzzaman SM, Rahman MM, Sobhan MJ.
    Bangladesh Med Res Counc Bull; 2013 Dec 30; 39(3):93-8. PubMed ID: 26118154
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.
    Morgan CL, Evans M, Toft AD, Jenkins-Jones S, Poole CD, Currie CJ.
    Clin Ther; 2011 Jan 30; 33(1):27-35. PubMed ID: 21397771
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.